SCHEMBL5490228

SCHEMBL5490228

CC(=O)Nc1cc(O)ccc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.57
HSD17B10 Q99714 1/20 0.57
ALDH1A1 P00352 7/20 0.52
CA12 O43570 3/20 0.52
CA1 P00915 3/20 0.52
CA2 P00918 3/20 0.52
CA7 P43166 3/20 0.52
CA9 Q16790 3/20 0.52
CA14 Q9ULX7 3/20 0.52
TSHR P16473 2/20 0.52
GRIK1 P39086 2/20 0.49
MAPT P10636 5/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
TDP1 Q9NUW8 2/20 0.47
HTT P42858 1/20 0.47
POLB P06746 2/20 0.47
CYP2C19 P33261 1/20 0.47
ALOX5 P09917 1/20 0.47
PTGS2 P35354 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10812626 0.87 ALDH1A1 (0.49) KDM4EHSD17B10ALDH1A1CA12CA1
SCHEMBL8533041 0.87 KDM4E (0.69) KDM4EHSD17B10ALDH1A1CA12CA1
SCHEMBL31451940 0.87 KDM4E (0.69) KDM4EHSD17B10ALDH1A1CA12CA1
SCHEMBL9621680 0.83 ALDH1A1 (0.46) KDM4EHSD17B10ALDH1A1CA12CA1
SCHEMBL14503727 0.82 KDM4E (0.54) KDM4EHSD17B10ALDH1A1CA12CA1
SCHEMBL6891543 0.81 KMT2A (0.55) KDM4EHSD17B10ALDH1A1GRIK1MEN1
SCHEMBL1304624 0.81 NEU3 (0.54) KDM4EHSD17B10ALDH1A1MAPTMEN1
SCHEMBL976774 0.81 MPO (0.58) KDM4EHSD17B10ALDH1A1GRIK1MAPT
SCHEMBL8505369 0.81 CA12 (0.55) HSD17B10ALDH1A1CA12CA1CA2
SCHEMBL1743408 0.81 ALDH1A1 (0.51) KDM4EALDH1A1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116478132-A 2, 5-disubstituted and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors 锐新医药公司 2023-07-25 CN disclosed
CN-116478131-A 2, 5-disubstituted and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors 锐新医药公司 2023-07-25 CN disclosed
CN-110914416-B Microorganism and method for producing cannabinoids and cannabinoid derivatives 加州大学董事会 2023-07-21 CN disclosed
CN-110840870-A Use of selective androgen receptor modulators for the treatment of metastatic and refractory breast cancer GTX公司 2020-02-28 CN disclosed
US-7205309-B2 Quinazoline derivatives HOFFMANN-LA ROCHE INC. (US) 2007-04-17 US disclosed
EP-1560816-A1 QUINAZOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-10 EP disclosed
US-20040029901-A1 Quinazoline derivatives HOFFMANN-LA ROCHE INC. 2004-02-12 US disclosed
WO-2004005265-A1 QUINAZOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029901-A1 Quinazoline derivatives GPR119, NQO2, CYP7A1 KDM4E 1709/4885HSD17B10 535/4885ALDH1A1 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.